AIM ImmunoTech Inc. (AIM) stock
AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.13−0.01 (-3.75%)
Close on Nov 18, 2026Market cap $3.98MP/E –Yield –
AIM ImmunoTech net income
Net income is the profit left for shareholders after every expense, interest and tax.
AIM ImmunoTech's net income for the twelve months ending Jun 30, 2026 was -$14.27M. For fiscal 2025 it was -$13.96M. The highest annual figure on record is -$7.50M in fiscal 2016.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.96M | – |
| FY2024 | Dec 31, 2024 | -$17.32M | – |
| FY2023 | Dec 31, 2023 | -$28.96M | – |
| FY2022 | Dec 31, 2022 | -$19.45M | – |
| FY2021 | Dec 31, 2021 | -$19.13M | – |
| FY2020 | Dec 31, 2020 | -$14.40M | – |
| FY2019 | Dec 31, 2019 | -$9.40M | – |
| FY2018 | Dec 31, 2018 | -$9.83M | – |
| FY2017 | Dec 31, 2017 | -$8.26M | – |
| FY2016 | Dec 31, 2016 | -$7.50M | – |
| FY2015 | Dec 31, 2015 | -$15.23M | – |
| FY2014 | Dec 31, 2014 | -$17.45M | – |
| FY2013 | Dec 31, 2013 | -$16.23M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.79M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.02M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.18M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.79M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.71M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.70M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.84M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.82M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.58M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.82M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.39M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.85M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.82M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.85M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.83M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.88M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.58M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.93M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.31M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.81M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.06M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.95M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.04M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.37M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.62M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.08M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.42M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.71M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.99M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.25M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.19M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.82M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.17M | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.86M | – |
| Q2 FY2016 | Jun 30, 2016 | -$1.30M | – |
See a number that looks wrong?